Covenant Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Covenant Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,045	Closed	-$226K	–	202
2020 Q2	$226K	Hold	2,045	–	–	0.1%	181
2020 Q1	$204K	Buy	2,045 +104	+5%	+$13.4K	0.11%	174
2019 Q4	$290K	Buy	1,941 +143	+8%	+$19.5K	0.14%	153
2019 Q3	$230K	Buy	1,798 +169	+10%	+$22.7K	0.12%	159
2019 Q2	$232K	Hold	1,629	–	–	0.12%	172
2019 Q1	$233K	Buy	+1,629	New	+$212K	0.13%	170

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Covenant Partners's JAZZ Position: Q3 2020 in Review

Covenant Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 2,045 shares — an estimated $226K sold.

Covenant Partners first reported a position in JAZZ in Q1 2019 and held it in 6 quarters. The position peaked at $290K in Q4 2019. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Covenant Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Covenant Partners sold 2,045 Jazz Pharmaceuticals shares in Q3 2020, an estimated $226K.
Covenant Partners first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Covenant Partners's Jazz Pharmaceuticals position peaked at $290K in Q4 2019.
389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Covenant Partners's 13F filing for Q3 2020, filed 10 Nov 2020.